Glenmark Pharma gains on receiving tentative ANDA approval for generic Vesicare Tablets

22 Jun 2017 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 635.60, up by 6.90 points or 1.10% from its previous closing of Rs. 628.70 on the BSE.

The scrip opened at Rs. 642.00 and has touched a high and low of Rs. 644.00 and Rs. 634.15 respectively. So far 12,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs. 600.00 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 644.00 and Rs. 626.10 respectively. The current market cap of the company is Rs. 17,934.00 crore.

The promoters holding in the company stood at 46.50%, while Institutions and Non-Institutions held 40.80% and 12.70% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Solifenacin Succinate Tablets, 5 mg and 10 mg, the generic version of Vesicare Tablets, 5 mg and 10 mg of Astellas Pharma US Inc.

According to IMS Health sales data for the 12 month period ending April 2017, the Vesicare Tablets, 5 mg and 10 mg market achieved annual sales of approximately $1.1 billion.

Glenmark’s current portfolio consists of 117 products authorized for distribution in the US marketplace and 68 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

2016.90 30.15 (1.52%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×